Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital Universitari Vall d'Hebron Research Institute
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18-60 years, inclusive
Diagnosis of RRMS (McDonald Criteria 2024, Montalban et al)
Expanded disability status scale (EDSS) score less than or equal to 5.5
Patients receiving a first line treatment with teriflunomide, dimethyl fumarate, interferon-beta or glatiramer acetate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a disease modifying therapy after the investigator has informed them of their possible respective benefits and possible adverse events
Not active RRMS patients (Lubin et al, 2014) for whom a switch in background therapy is not anticipated, based on the Investigator's judgment.
At enrollment, the patient is not expected to require a change in DMT
Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product
For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period
Ability to comply with the study protocol
Patients must sign and date a written informed consent prior to entering the study
You may not be if
Relapse the month before enrollment
Use of corticosteroids the month before enrollment
Use of antibiotics three months before enrollment
Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment
Patients suffering from any type of bowel disease
Pregnant or breastfeeding or intending to become pregnant during the study.
Clareo Health | The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis
